Literature DB >> 26276890

Improving the Diagnosis of Infective Endocarditis in Prosthetic Valves and Intracardiac Devices With 18F-Fluordeoxyglucose Positron Emission Tomography/Computed Tomography Angiography: Initial Results at an Infective Endocarditis Referral Center.

María N Pizzi1, Albert Roque2, Nuria Fernández-Hidalgo2, Hug Cuéllar-Calabria2, Ignacio Ferreira-González2, María T Gonzàlez-Alujas2, Gerard Oristrell2, Laura Gracia-Sánchez2, Juan J González2, José Rodríguez-Palomares2, Manuel Galiñanes2, Olga Maisterra-Santos2, David Garcia-Dorado2, Joan Castell-Conesa2, Benito Almirante2, Santiago Aguadé-Bruix2, Pilar Tornos2.   

Abstract

BACKGROUND: The diagnosis of infective endocarditis (IE) in prosthetic valves and intracardiac devices is challenging because both the modified Duke criteria (DC) and echocardiography have limitations in this population. The added value of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) and (18)F-FDG PET/CT angiography (PET/CTA) was evaluated in this complex scenario at a referral center with a multidisciplinary IE unit. METHODS AND
RESULTS: Ninety-two patients admitted to our hospital with suspected prosthetic valve or cardiac device IE between November 2012 and November 2014 were prospectively included. All patients underwent echocardiography and PET/CT, and 76 had cardiac CTA. PET/CT and echocardiography findings were evaluated and compared, with concordant results in 54% of cases (κ=0.23). Initial diagnoses with DC at admission, PET/CT, and DC+PET/CT were compared with the final diagnostic consensus reached by the IE Unit. DC+PET/CT enabled reclassification of 90% of cases initially classified as possible IE with DC and provided a conclusive diagnosis (definite/rejected) in 95% of cases. Sensitivity, specificity, and positive and negative predictive values were 52%, 94.7%, 92.9%, and 59.7% for DC; 87%, 92.1%, 93.6%, and 84.3% for PET/CT; and 90.7%, 89.5%, 92%, and 87.9% for DC+PET/CT. Use of PET/CTA yielded even better diagnostic performance values than PET/nonenhanced CT (91%, 90.6%, 92.8%, and 88.3% versus 86.4%, 87.5%, 90.2%, and 82.9%) and substantially reduced the rate of doubtful cases from 20% to 8% (P<0.001). DC+PET/CTA reclassified an additional 20% of cases classified as possible IE with DC+PET/nonenhanced CT. In addition, PET/CTA enabled detection of a significantly larger number of anatomic lesions associated with active endocarditis than PET/nonenhanced CT (P=0.006) or echocardiography (P<0.001).
CONCLUSIONS: (18)F-FDG PET/CT improves the diagnostic accuracy of the modified DC in patients with suspected IE and prosthetic valves or cardiac devices. PET/CTA yielded the highest diagnostic performance and provided additional diagnostic benefits.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  endocarditis; heart; positron-emission tomography; tomography; valves

Mesh:

Substances:

Year:  2015        PMID: 26276890     DOI: 10.1161/CIRCULATIONAHA.115.015316

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  66 in total

1.  Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis.

Authors:  Nuria Vallejo Camazon; Lourdes Mateu; Germán Cediel; Laura Escolà-Vergé; Nuria Fernández-Hidalgo; Mercedes Gurgui Ferrer; Maria Teresa Perez Rodriguez; Guillermo Cuervo; Raquel Nuñez Aragón; Cinta Llibre; Nieves Sopena; Maria Dolores Quesada; Elisabeth Berastegui; Albert Teis; Jorge Lopez Ayerbe; Gladys Juncà; Francisco Gual; Elena Ferrer Sistach; Ainhoa Vivero; Esteban Reynaga; Maria Hernández Pérez; Christian Muñoz Guijosa; Lluisa Pedro-Botet; Antoni Bayés-Genís
Journal:  Cardiol J       Date:  2021-05-25       Impact factor: 2.737

2.  Quantifying FDG uptake to diagnose cardiac device infections: When and how should we do it?

Authors:  Ron Blankstein; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2015-10-22       Impact factor: 5.952

3.  Nuclear imaging for patients with a suspicion of infective endocarditis: Be part of the team!

Authors:  Fabien Hyafil; François Rouzet; Dominique Le Guludec
Journal:  J Nucl Cardiol       Date:  2015-12-29       Impact factor: 5.952

Review 4.  18F-FDG-PET/CT Imaging to Diagnose Septic Emboli and Mycotic Aneurysms in Patients with Endocarditis and Cardiac Device Infections.

Authors:  Nidaa Mikail; Khadija Benali; Besma Mahida; Jonathan Vigne; Fabien Hyafil; François Rouzet; Dominique Le Guludec
Journal:  Curr Cardiol Rep       Date:  2018-03-06       Impact factor: 2.931

5.  Meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis.

Authors:  Maryam Mahmood; Ayse Tuba Kendi; Saira Ajmal; Saira Farid; John C O'Horo; Panithaya Chareonthaitawee; Larry M Baddour; M Rizwan Sohail
Journal:  J Nucl Cardiol       Date:  2017-10-30       Impact factor: 5.952

6.  Distinctive FDG-PET/CT Findings in Acute Neurological Hospital Care.

Authors:  Josef G Heckmann; Wolfgang Niedermeier; Markus Büchner; Bernhard Scher
Journal:  Neurohospitalist       Date:  2018-10-15

7.  Quantification of FDG uptake in patients with a suspicion of prosthetic valve endocarditis: Part of the problem or part of the solution?

Authors:  Fabien Hyafil; François Rouzet; Dominique Le Guludec
Journal:  J Nucl Cardiol       Date:  2017-07-24       Impact factor: 5.952

8.  FDG PET/CT in prosthetic heart valve endocarditis: There is no need to wait.

Authors:  A M Scholtens; R P J Budde; M G E H Lam; H J Verberne
Journal:  J Nucl Cardiol       Date:  2017-05-30       Impact factor: 5.952

Review 9.  Infective Endocarditis in the Elderly: Diagnostic and Treatment Options.

Authors:  M P Ursi; E Durante Mangoni; R Rajani; J Hancock; J B Chambers; B Prendergast
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

10.  18F-FDG PET/CT in the diagnosis of prosthetic valve endocarditis.

Authors:  Erika Fagman; Martijn van Essen; Johan Fredén Lindqvist; Ulrika Snygg-Martin; Odd Bech-Hanssen; Gunnar Svensson
Journal:  Int J Cardiovasc Imaging       Date:  2015-11-26       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.